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Background: A number of valuable candidates as tuberculosis vaccine have been reported, some of which have
already entered clinical trials. The new vaccines, especially subunit vaccines, need multiple administrations in order
to maintain adequate life-long immune memory: this demands for high production levels and degree of purity.
Results: In this study, TB10.4, Ag85B and a TB10.4-Ag85B chimeric protein (here-after referred as full) - immunodominant
antigens of Mycobacterium tuberculosis - were expressed in Escherichia coli and purified to homogeneity. The rational
design of expression constructs and optimization of fermentation and purification conditions allowed a marked increase
in solubility and yield of the recombinant antigens. Indeed, scaling up of the process guaranteed mass production of all
these three antigens (2.5-25 mg of pure protein/L cultivation broth). Quality of produced
soluble proteins was evaluated both by mass spectrometry to assess the purity of final preparations, and by circular
dichroism spectroscopy to ascertain the protein conformation. Immunological tests of the different protein products
demonstrated that when TB10.4 was fused to Ag85B, the chimeric protein was more immunoreactive than either of the
immunogenic protein alone.
Conclusions: We reached the goal of purifying large quantities of soluble antigens effective in generating immunological
response against M. tuberculosis by a robust, controlled, scalable and economically feasible production process.
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Tuberculosis (TB) is one of the leading cause of morbidity
and mortality in humans, and it represents a major public
health problem in many countries [1,2]. Despite Mycobac-
terium tuberculosis, the causative agent of TB, being iden-
tified by Robert Koch in 1882, major gaps remain in our
knowledge of the complex cell life of this pathogen.
Designing an effective vaccine against TB is an inter-
national research priority since human trials have demon-
strated a highly variable protective efficacy of the currently
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reproduction in any medium, provided the orGuerin (BCG) [2]. BCG is protecting against severe
forms of childhood TB, but it is of limited use against
adult pulmonary disease and its protective efficacy
wanes significantly over a period of 10–15 years [3,4].
Due to the increasing incidence of multi- and extreme-
drug-resistant M. tuberculosis clinical isolates, chemo-
therapeutic treatment options are often limited, toxic
and of questionable efficacy. An improved second gen-
eration vaccine that can act as an efficient prophylactic
vaccine and/or a vaccine that can boost immunity in
BCG-vaccinated individuals is, therefore, urgently needed
[5].
The availability of the M. tuberculosis genome se-
quence and the current efforts to sequence a large num-
ber of additional mycobacterial genomes [5] have set the
stage for a post-genomics approach to the identification,
production and trials of novel antigens. Gene families ofLtd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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and tested in vivo. Among them, Ag85 complex (Ag85
A, B, C), the most abundant protein secreted by M.
tuberculosis, attracts considerable interest for a new TB
vaccine development. Ag85B, a mycolyl transferase, is
among the most potent antigen species yet identified,
which induces both humoral and cell-mediated immune
response in M. tuberculosis-infected subjects [6,7]. An-
other gene family, the esat-6 one, has been demonstra-
ted to encode several immunodominant proteins that
are strongly recognized by the immune systems of diffe-
rent animal models of TB, as well as by T cells from
human beings exposed to M. tuberculosis [8]. TB10.4 is
a low molecular mass protein belonging to esat-6 family.
This protein represents a valuable vaccine candidate
since it is highly conserved in different M. tuberculosis
clinical isolates obtained from different geographical
locations and it is strongly recognized by T-cells from
BCG-vaccinate donors as well as from TB patients [8].
The subunit vaccine composed of Ag85B-TB10.4 has
been also designed and shown to generate a strong,
specific immune response in mice. Vaccinating mice
with this subunit vaccine induced a level of protection
against TB comparable to that produced by BCG and
better than that achieved by vaccinating with either of
the single proteins [6].
To support further evaluation of M. tuberculosis selec-
ted antigens and their modified recombinant variants as
candidates for the second-generation vaccines against
TB, a reliable and robust production process is urgently
needed today. Vaccine candidates should be produced in
the quantity and quality needed for preclinical and cli-
nical studies. Although it is possible to purify native an-
tigens from M. tuberculosis, it is more efficient and safer
to express them in an heterologous host such as Escheri-
chia coli and then optimize the recombinant protein
production process [9,10]. With this approach, molecu-
lar engineering may be used to redesign antigens of
interest and to combine and fuse two antigens such in
the case of the Ag85B-TB10.4 subunit vaccine. Unfor-
tunately until now most of the recombinant antigens
currently explored as TB vaccine candidates have been
purified in very low amount from E. coli, making the
production process for large scale use extremely costly.
Due to the tendency of incorrect protein folding and
aggregation when over-expressed in an heterologous
system, these antigens often accumulated in inclusion
bodies (IBs), from whom they were recovered by solu-
bilisation with denaturant agents followed by tailored
procedures of protein renaturation [11,12]. The use and
the following removal of large amount of denaturant
agents increase the production cost and require add-
itional steps of quality control. In addition, recent data
demonstrated that M. tuberculosis antigens purified fromIBs do not retain the conformation adopted by the solu-
ble counterparts, raising the question of whether these
recombinant proteins keep the same immunogenicity of
the native antigens [12].
In this paper, we have adopted different strategies to
express recombinant Ag85B, TB10.4 and the fused
TB10.4-Ag85B chimeric protein, with the aim of puri-
fying these antigens in a soluble form from E. coli cells.
Chemical identity and stability, immunological activity
and, last but not least, production feasibility and cost of
the produced recombinant proteins have been assessed to
sustain their further development as vaccine candidates
per se or as a scaffold for further structural modifications.
Production and purification processes of these immu-
nogenic proteins have been successfully scaled up from
shaken flasks to bench bioreactors.
Results
Production and purification of Trx-TB10.4 and TB10.4
The synthetic cDNA coding for TB10.4 (GenBank Acces-
sion no. CAA17363.1) was optimized to match the codon
usage for E. coli expression (see Additional file 1: Figures
S1 and S2). Codon usage optimization was essential since
E. coli is a low G +C content (~ 50%) Gram-negative
bacterium while M. tuberculosis is a high G + C (> 65%)
Gram-positive actinobacterium. The cDNA was subclo-
ned into pET32b plasmid in frame with nucleotidic se-
quence coding for thioredoxin (Trx), with a His6-tag
sequence and with a sequence recognized by enterokinase
(EK) – these sequences are located at the N-terminus of
TB10.4 (Figure 1). Trx is a 12 kDa protein that remarkably
increases the solubility of fusion proteins [13]. The
chimeric Trx-TB10.4 protein (261 amino acids, molecular
mass 28.1 kDa, Table 1 and Figure 1) was produced in
E. coli using BL21(DE3) strains. Basal expression was
performed in LB medium, adding 0.1 mM IPTG when
OD600nm reached 0.6-0.8 and collecting cells after add-
itional 4 hours of growth at 18°C: using these conditions,
a fairly good amount of chimeric protein was produced as
soluble form and about 2 mg/L of > 85% pure Trx-TB10.4
was purified after a single-step purification on nickel-
affinity chelating column. Optimization of the expression
conditions (i.e. growing cells for 16 hours at 18°C after
IPTG addition) increased significantly the production of
the soluble form of the chimeric protein: 12 mg/L of
> 95% pure Trx-TB10.4 was purified by metal-chelating
chromatography (Table 2, see Additional file 2: Figures
S3A, B and C). Mass spectrometry (MS) spectrum of the
fusion protein reported in Figure 2A confirmed the iden-
tity and purity of the fused protein, indicating a molecular
mass corresponding to the isoform lacking methionine
at the N-terminal.
Complete cleavage of Trx-TB10.4 fusion protein was
obtained using 3 U of recombinant enterokinase (rEK)
Figure 1 Scheme of the recombinant proteins as produced upon cloning in pET32b (Trx-TB10.4, Trx-Ag85B and Trx-full) or pColdI
(His-full1 and His-full2) vectors. Trx: thioredoxin (116 amino acids, aa). The arrow indicates the EK cleavage site. The entire amino acid
sequences are reported in the Additional file 1: Figure S2.
Table 1 Chemico-physical parameters of the recombinant
proteins as produced upon cloning in pET32b or pColdI
Protein Length (aa) Molecular mass (Da) Theoretical pI
Trx-TB10.4 261 28,133.6 5.06
TB10.4 103 11,076.3 4.44
Trx-Ag85B 450 48,405.2 5.11
Ag85B 292 31,347.9 4.77
Trx-full 546 58,777.7 4.99
His-full1 414 44,865.9 5.11
full1 388 41,720.5 4.71
His-full2 397 43,060.0 5.53
Theoretical isoelectric point (pI) was calculated by ExPASyBioinformatic
Resource Portal (http://www.expasy.org/) using ProtParam tool.
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and TB10.4) were separated by metal-chelating chro-
matography (see Additional file 2: Figure S3D and E). The
expected mature recombinant TB10.4 is a 103 amino acid
long protein (Table 1), bearing a seven amino acid residue
pre-sequence (AMAISDP) at the N-terminal region
originating from the cloning procedure (Figure 1). MS
analysis of TB10.4 preparation (Figure 2B) showed the
presence of the full-length TB10.4, with an average mass
of 11076.0 Da (nominal mass 11076.36 Da), and an
additional product (accounting for ca. 40% of the total
protein) with a calculated average mass of 10776.0 Da.
This mass shift (−300 Da) corresponds to the lack of three
C-terminal amino acids (WGG) from the mature TB10.4.
This secondary cleavage might be due to the AEAAK
sequence – resembling the EK consensus sequence
(i.e. DDDDK) – that is located just before the three
C-terminal amino acids. When the TB10.4 preparation was
Table 2 Production yield of purified recombinant
Trx-TB10.4, Trx-Ag85B (chimeric and single antigens,
after proteolytic cleavage), and His-full2 by E. coli cells












Trx-TB10.4 Flasks 4.8 12 4c
Bioreactor 8.5 80 25c
Trx-Ag85B Flasks 10.5 9 4.7c
Bioreactor 19.5 30 16c
His-full2 Flasks 6.5 / 0.5
Bioreactor 6.5 / 2.5
agrams of E. coli cells (wet weight) per liter of cultivation broth at the
harvest time.
bmilligrams of protein obtained upon purification by nickel-affinity chromatog-
raphy per liter of cultivation broth.
cmilligrams of protein obtained upon proteolytic cleavage and separation by
nickel-affinity chromatography per liter of cultivation broth.
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degradation products appeared, whose formation was
instead avoided adding a specific EK inhibitor: this result
indicates a persisting proteolytic activity by residual EK
not (completely) removed by the chromatography on
HiTrap chelating column following the cleavage step (see
above). Formation of the truncated form was avoidedFigure 2 MS analyses of purified Trx-TB10.4 and TB10.4. Deconvoluted
TB10.4 before the proteolytic cleavage optimization; C) purified TB10.4 afte
further incubation at 37°C, for 24 hours.using an optimized rEK (Tag · Off High Activity rEK) –
2 U per mg of substrate protein, 6 hours of incubation
at 25°C – and removing rEK using EKapture Agarose
(Figure 2C). Pure mature TB10.4 was recovered (Table 2)
and its stability at room temperature was checked by MS
analysis: following the optimized cleavage procedure, no
secondary (truncated) forms were apparent. When the
same preparation was further incubated for 24 hours at
37°C in the absence of an EK inhibitor ca. 74% of the
mature TB10.4 form was still present (Figure 2D).
Production and purification of Trx-Ag85B and Ag85B
The synthetic cDNA coding for the mature form (285
amino acids) of Ag85B lacking the region encoding for
the N-terminal 40 residues corresponding to the putative
signal peptide (UniProtKB/Swiss-Prot Accession no.
P0C5B9.1; PDB Accession no. 1F0N_A), also optimized
for E. coli expression, was subcloned into pET32b plas-
mid, in frame with nucleotidic sequence coding for Trx,
with a His6-tag sequence and with a sequence recognized
by EK – these sequences are located at the N-terminus of
Ag85B (Figure 1). The Trx-Ag85B chimeric protein is
450 amino acid long and its molecular mass is 48.4 kDa
(Table 1 and Figure 1, see also Additional file 1:
Figures S1 and S2). Using the same standard conditions set
up for Trx-TB10.4, a very low amount of solublespectra from intact ESI-LIT-MS analyses of: A) Trx-TB10.4; B) purified
r the proteolytic cleavage optimization and D) the same sample after
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tein (< 1 mg/L) was isolated by metal chelating chroma-
tography. In order to improve the amount of protein
produced, a number of expression conditions - using dif-
ferent growth media (LB, TB, SB and minimal medium
M9), adding 0.1 or 1.0 mM IPTG when OD600nm reached
0.7, 2 or after overnight growth (saturation condition) -
were tested. In all cases, following IPTG addition, cells
were grown at 18°C and collected after 4 hours, and the
expression level was assessed by Western blot using
anti-His-tag antibody. The largest amount of soluble
Trx-Ag85B was obtained growing cells in SB medium
and inducing expression with 0.1 mM IPTG at an
OD600nm = 2 (see Additional file 2: Figure S4). Further
improvement was obtained growing cells for additional
16 hours (overnight) after IPTG addition. Using these
conditions, ca. 25-30% of the chimeric protein was sol-
uble (Additional file 2: Figure S5B and C) corresponding
to a productivity of 20 mg/L: 9 mg/L of Trx-Ag85B (> 95%
purity degree) were isolated after a single-step purifica-
tion on nickel-affinity column chromatography (Table 2,
see Additional file 2: Figure S5A, B and C). MS
spectrum of the fusion protein confirmed its identity
and purity (Figure 3A).
Complete maturation of the fusion protein was ob-
tained using 3 U of rEK per mg of Trx-Ag85B at 20°C
for 16 hours (Table 2, see Additional file 2: Figure S5DFigure 3 MS analyses of purified Trx-Ag85B and Ag85B.
Deconvoluted spectra from intact ESI-LIT-MS analyses of: A) purified
Trx-Ag85B; B) mature Ag85B after proteolytic cleavage.and E). The mature Ag85B obtained by rEK cleavage is a
292 amino acid long protein (molecular mass: 31.3 kDa,
see Table 1 and Figure 1), bearing at the N-terminal end
a pre-sequence (AMAISDP) originating from the cloning
procedure. MS analysis confirmed the identity and purity
of the mature Ag85B, with a determined mass of
31346.0 Da (nominal mass 31347.9 Da, Figure 3B).
Production and purification of TB10.4-Ag85B (full) protein
The synthetic cDNA coding for the fusion protein
obtained by the combination of the nucleotide sequences
of TB10.4 and Ag85B (namely, full protein) was sub-
cloned into pET32b plasmid, in frame with the sequence
coding for Trx, with a His6-tag sequence and with a
sequence recognized by rEK (useful to remove Trx). The
chimeric protein Trx-TB10.4-Ag85B (Trx-full) is 546
amino acid long (molecular mass is 58.8 kDa, Table 1
and Figure 1). Since the aim of this work was to produce
soluble antigens, the TB10.4-Ag85B fusion protein was
preferred to the Ag85B-TB10.4 version because the latter
chimera was never produced in a significant amount as
soluble protein [6,12]. The solubility of Trx-TB10.4-
Ag85B protein was reported to be >10-fold increased
compared to that of Trx-Ag85B-TB10.4 [12].
Trials for the expression of Trx-full were conducted
using the same conditions set up for the single antigenic
proteins. Western blot analysis of the produced Trx-full in
cell extracts showed that a consistent fraction (80-90%) of
the fusion protein accumulated into the insoluble fraction,
being only traces of the protein detectable in the soluble
fraction (and together with proteolytic products, data not
shown). Co-expression of different chaperon proteins
(AraB/DnaK/DnaJ/GrpE or GroES/GroEL/TiG) did not
increase the solubility of the fusion protein. Purification of
soluble Trx-full yielded less than 1 mg/L, with purity
inferior to 50% (data not shown).
To obtain higher amounts of the full protein as soluble
form, the chimeric cDNA was inserted into pColdI plas-
mid, a system based on low-temperature expression
gene (cold shock gene) specifically designed to improve
the solubility in E. coli of heterologous proteins [14].
Two different gene constructs were prepared, named
His-full1 and His-full2: in both cases, the full protein
bears the His-tag at the N-terminus without thioredoxin
(Figure 1). His-full1 is a 414 amino acid long protein
(molecular mass of 44.9 kDa, Table 1 and Figure 1, see
also Additional file 1: Figure S2), still bearing at the N-
terminal region the sequence recognized by EK. Expres-
sion trials for His-full1 were conducted in BL21(DE3)
and BL21(DE3)pLysS E. coli strains, growing cells in LB,
TB or SB media at 37°C, adding 1.0 mM IPTG when
cells reached early/middle exponential growth phase
(OD600 nm = 0.6-0.7 for LB and 1.2-1.5 for TB and SB) or
middle/late exponential growth phase (OD600 nm = 1.2-
Figure 4 MALDI-TOF/TOF mass spectrum of the doubly-charged
protein His-full2. Two principal isoforms can be observed,
corresponding to the natrium adduct (at 21557.68 m/z) and to the
natrium/synapinic acid adduct (21668.3 m/z).
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grown for additional 20 hours at 15°C prior harvesting.
Western blot analysis of cells extracts showed the major
part of the expressed His-full1 (ca. 80%) accumulated as
IBs. A maximum yield of 1.3 mg/L of His-full1 with ca.
85% purity was obtained after a single-step purification
(on HiTrap Chelating chromatography) from cells grown
in TB medium added with 5 g/L of NaCl and by adding
further 25 g/L of NaCl at the moment of induction with
IPTG, according to a protocol previously developed in
our lab [15] (data not shown). Incubation of purified
His-full1 with EK in the same condition used for Trx-
Ag85B (3 U/mg His-full1, for 16 hours at 20°C) yielded
a consistent amount of proteolytic products, indicating a
high sensitivity to proteolysis of the chimeric protein
(not shown).
In order to eliminate the EK cleavage step and to
reduce the length of the additional sequence at the N-
terminal end of the chimeric protein, site-directed muta-
genesis of the full cDNA introduced a NdeI restriction
site allowing its cloning in pColdI plasmid using NdeI
and EcoRI restriction sites (Figure 1). By this strategy, a
397 amino acid long protein (namely His-full2, molecu-
lar mass: 43.06 kDa, Table 1 and Figure 1) was designed.
His-full2 contains 16 additional amino acids including
the His6-tag sequence (MNHKVHHHHHHIEGRH, see
Additional file 2: Figure S2) at the N-terminal end vs.
the 33 amino acids present in the previous TB10.4-
Ag85B chimeric proteins.
Expression trials carried out on His-full2 showed that,
similarly to Trx-Ag85B (see the paragraph above), the best
expression conditions were based on the use of SB
medium and induction with 0.1 mM IPTG at OD600nm = 2.
An increase in the production of the recombinant protein
was obtained using NaCl in the medium (10 g/L) and by
adding further 25 g/L of NaCl simultaneously to IPTG
(not shown). As reported in Table 2 and explained below,
His-full2 production increased significantly when scaled-
up to a 3 L bioreactor. However, the major part of the
fusion protein again accumulated as IBs (see Additional
file 2: Figure S6B and C, that refer to cells produced at
bioreactor scale). About 0.5 mg/L of His-full2 with a
purity of ca. 90% was obtained after the HiTrap Chelating
chromatography performed under optimized conditions
(linear gradient from 100 to 250 mM imidazole in 3-
column volumes, see Additional file 2: Figure S6A and C).
Despite the lower yield than for the His-full1, this second
chimeric protein had the advantage to skip the EK cleav-
age step. MALDI-TOF/TOF MS spectrum of the chimeric
protein is given in Figure 4. The two principal ions ob-
served correspond to the doubly charged natrium adduct
(at 21557.68m/z) and to the doubly charged natrium/
synapinic acid adduct (21668.3m/z) of the His-full2
protein, confirming its identity.Scaling up of protein antigen production
After optimization at the shaken flask-scale, processes
and production media were scaled up in 3 L bioreactor.
As shown by the parameters controlled on line (dO2 and
pH) and by densitometric analysis of cell growth during
batch cultivation (Figure 5), the growth of recombinant
E. coli BL21(DE3) cells holding the pColdI-His-full2 was
faster than those transformed by pET32b-Trx-TB10.4
and pET32b-Trx-Ag85B, even if a lower temperature
was adopted after induction of protein expression (15°C
for His-full2 production vs. 18°C for Trx-TB10.4 and
Trx-Ag85B). In 6 hours from inoculum, maximum bio-
mass was achieved and dO2 was completely depleted in
cells producing His-full2. In Trx-Ag85B production,
oxygen depletion occurred after 8 hours from inoculum
and the phase of oxygen limitation lasted for further ten
hours. E. coli Trx-TB10.4-producing cells showed a simi-
lar time course of oxygen consumption, but the levels of
dO2 never decreased below 50% of saturation, indicating
a minor respiratory activity; growth of the culture was
slower and reached a lower level of biomass production
(in wet weight: 19.5 and 8.5 g/L were recovered after
24 hours from cells producing Trx-Ag85B or Trx-
TB10.4, respectively, see Table 2). For both Trx-Ag85B
or Trx-TB10.4 producing cells, after an initial slight
decrease, pH tended to alkalinization in the following
fermentation phase. In cells producing His-full2, a
Figure 5 Time course of pH (○, solid line), dO2 (♦, solid line)
and OD600nm (●, dashed line) in 3 L batch cultivation trials of
recombinant E. coli BL21(DE3) cells producing M. tuberculosis
immunogenic proteins. A) E. coli BL21(DE3) cells containing
pET32b-Trx-TB10.4 plasmid and grown in LB medium. B) E. coli BL21
(DE3) cells containing pET32b-Trx-Ag85B plasmid and grown in SB
medium. C) E. coli BL21(DE3) cells containing pColdI-His-full2 and
growing in SB/NaCl medium. Temperature (■, dashed line) was kept
constant at 37°C before IPTG addition and then reduced to 18°C for
Trx-TB10.4 and Trx-Ag85B production, and at 15°C for His-full2 produc-
tion, until harvest. The induction of protein expression was done at
OD600nm = 0.8 with 0.1 mM IPTG for Trx-TB10.4, at OD600nm = 2 with
0.1 mM IPTG for Trx-Ag85B, and at OD600nm = 2 with 0.1 mM IPTG for
His-full2. Biomass (wet weight) collected at the harvest time was
8.5 g/L for Trx-TB10.4, 19.5 g/L for Trx-Ag85B and 6.5 g/L for His-full2.
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in oxygen level after the initial sharp reduction occurred,
probably reflecting a stress status arresting cell proliferation
after IPTG addition and growth temperature reduction.
Notwithstanding the higher OD600nm of pColdI-His-full2
containing cells, final biomass was only 6.5 g/L in wet
weight (Table 2).
Table 2 shows that recombinant E. coli cells produced
more biomass in the stirred bioreactors than in the
shaken flasks, due to the better oxygen distribution in
the larger scale system which sustains higher density
cultivation. Application of the same protocols of metal-
chelating chromatography described above to purify
Trx-Ag85B, Trx-TB10.4 or His-full2 gave a significantly
increased purification yield from biomass generated in
bioreactor than from shaken flasks: 9.4 mg pure Trx-
TB10.4, 1.5 mg pure Trx-Ag85B and 0.38 mg pure His-
full2 per gram of biomass were achieved at bioreactor
scale compared to figures of 2.5 mg Trx-TB10.4,
0.85 mg Trx-Ag85B and 0.076 mg His-full2 per gram of
biomass obtained at flask-scale. These data indicate a
beneficial effect of scaling up on both the volumetric
productivity (mg of protein per liter of cultivation broth)
and the specific productivity (mg of protein per gram of
biomass). In the case of His-full2, protein purification
was feasible only at the bioreactor scale, due to low
specific productivity of cells grown in flasks: the soluble
form of His-full2 increased from 5 to ca. 15% of the total
expressed chimeric protein shifting from flasks to bio-
reactor. In the case of Trx-TB10.4 and Trx-Ag85B, the
step of EK digestion and mature protein recovery was
not affected by the scaling up, being of about one third
for TB10.4 and 50% for Ag85B independently if biomass
was generated in flasks or in bioreactors. Identity of the
fused and mature antigens was confirmed by MS ana-
lyses (spectra overlap with those reported in Figure 2A
and C, Figure 3A and B, and Figure 4).
Biochemical and immunological characterization of the
protein antigens
The quality of the recombinant antigenic proteins was
assessed in terms of purity by SDS-PAGE (Additional
file 2: Figure S7) and MS analyses (see above) and in
terms of protein conformation by circular dichroism
(CD) spectroscopy. The secondary structure of pure
Ag85B (as determined by the far-UV CD spectra repor-
ted in Figure 6A) is composed of both α-helices and β-
sheets (ca. 26 and 23% as estimated by k2D2 software
vs. 37 and 20% from the crystal structure, pdb code
1F0N), while for TB10.4 the signal for α-helices only is
apparent, in good agreement with the known 3D struc-
ture (55% α-helix content, pdb code 1F0N) and previous
analyses [12]. Similarly, the signal for the tertiary structure
significantly differs for the two M. tuberculosis antigens,
Figure 6 CD spectra of TB10.4 (continuous line), Ag85B
(dashed line) and His-full2 (dotted line). A) Far-UV CD spectra
(protein concentration: 0.1 mg/mL). B) Near-UV CD spectra
(protein concentrations: 0.45, 0.35 and 0.85 mg/mL for TB10.4, Ag85B
and His-full2, respectively). All spectra were collected in 10 mM
ammonium acetate, pH 7, at 15°C.
Figure 7 Analysis of the antibody reactivity to the expressed
protein antigens. Ag85B, TB10.4 and His-full2 proteins were
adsorbed at different concentrations on ELISA plate (as indicated on
abscissa) and tested with active-TB sera at 1:100 dilution. The
reactivity is reported as difference of the OD (ΔOD) observed for
the sera and in absence of sera as median, 25–75 percentile range
(box), and minimum and maximum (line) observed for the 8 tested
active-TB patients.
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resemble those of Ag85B, according to the fact that
Ag85B molecular mass is 3-fold higher than that of
TB10.4 (Table 1). All together, spectral analyses indicate
the acquisition of a well defined protein conformation for
all the recombinant soluble antigenic proteins.
Immunological activity of the recombinant proteins
was then assessed by the capability of the proteins to be
recognised as antigen by sera (ELISA) or T cells (ELI-
SPOT) of active-TB patients. In a first set of ELISA tests,variable concentrations of the antigens (100, 200 and
400 ng) were adsorbed and tested with TB sera at 1:100
dilution. For the Ag85B and the His-full2 proteins, a
dose dependent reactivity of TB sera vs. the concen-
tration of the antigen adsorbed on the ELISA plate was
observed (Figure 7). On the contrary, almost no reactiv-
ity was observed for the TB10.4 protein, in agreement
with previous studies [6-8]. Furthermore, in order to
assess the specificity of the observed reactivity against
the M. tuberculosis recombinant Ag85B and His-full2
protein antigens, antibody titre was determined for each
control and active-TB serum by end final point dilution
test. As shown in Additional file 3: Figure S8, TB sera
present a significant higher antibody titre (median 600)
than controls (median 100, p < 0.001) for the Ag85B
protein antigen. Similar results were obtained with the
chimeric His-full2 protein (TB patients median titre
1200, controls median titre 200, p < 0.001). These data
were further confirmed by analysing the single control
and active-TB sera reactivity at 1:200 dilution, as repor-
ted in Additional file 3: Figure S9.
Figure 8 shows the results of the T-cell reactivity
observed in active TB-patients and healthy controls.
Control and active-TB subjects presented a similar
T-cell response capability for the Staphylococcus aureus
Enterotoxin B (SEB) superantigen used as positive con-
trol. For all of the M. tuberculosis recombinant proteins
tested, a significant higher number of IFN-γ producing
effector T-cells were observed in active-TB patients
Figure 8 Analysis of the T-cell reactivity against Ag85B, TB10.4
and His-full2 proteins and positive control superantigen (SEB).
Control (white boxes) and active-TB (grey boxes) PBMCs were tested
in ELISPOT and the IFN-γ positive effector T-cells enumerated and
referred to 1×106 PBMCs (ordinate). The number of spots observed
in absence of antigen was subtracted. Data are reported as median,
25–75 percentile range (box), and minimum and maximum (line)
observed in subject groups of the study population presenting an
immunological valid test (active-TB n = 10; healthy controls n = 6).
Piubelli et al. Microbial Cell Factories 2013, 12:115 Page 9 of 14
http://www.microbialcellfactories.com/content/12/1/115compared to MTB-unexposed controls -Ag85B: controls
312 ± 363 (mean ± std) spots/million peripheral blood
mononuclear cells (PBMCs), active-TB 2361 ± 1863;
p < 0.0001; TB10.4: controls 184 ± 209, active-TB
2009 ± 1901; p < 0.0001; His-full2: controls 701 ±
859, active-TB 22183 ± 1173; p = 0.0381 - confirming
that the cell mediated immune response is effectively
triggered by the antigens produced during this study.
Discussion
A number of interlinking cells and mechanisms are
involved in the immune response following M. tubercu-
losis infection. Delivering effective hits to infected target
cells represents the way to push the host response to
control infection and, possibly, to eradicate bacteria. At
present, the development of new TB vaccines follows
two main approaches: a) replacing BCG by either im-
proved recombinant BCG or by genetically attenuated
M. tuberculosis; b) developing subunit vaccines mostly
based on recombinant proteins. In past years, significant
progress has been made in producing recombinant anti-
genic proteins, mostly fusion proteins that combine
immunodominant antigens of M. tuberculosis, e.g., the
Hybrid 1 fusion protein which consists of Ag85B fused
to ESAT6, or Hyvac 4 consisting of Ag85B fused to the
antigen TB10.4 [16]. Our aim is to produce well-known
M. tuberculosis antigens with a native-like structure in
order to preserve conformational epitopes in addition to
the sequential ones. The importance of native-like struc-
ture has been made apparent by the structural vaccino-
logy approach, in which the three-dimensional structural
information is used to design novel and improved
vaccine antigens. As stated by [17]: “We now routinelydetermine structures of vaccine antigens as a central task
in vaccine optimization. The essential insights that anti-
body epitopes are conformational, extended protein surfa-
ces and that short, floppy peptides rarely elicit protective
antibodies are essential for selecting vaccine research stra-
tegies that have a high probability of success”.
In the present study, solubility enhancement by N-
terminal thioredoxin fusion and/or by optimization of
fermentation conditions was investigated for the recom-
binant antigens Ag85B, TB10.4 and full (TB10.4-Ag85B).
Protein over-expression in E. coli frequently leads to the
formation of IBs; obtaining proteins from the IBs has
several drawbacks. Despite these disadvantages, the re-
combinant M. tuberculosis antigens Ag85B [18], TB10.4
[19], and Ag85B-TB10.4 [6] have been previously puri-
fied from IBs and formulated into subunit vaccines
although their immunogenicity was not the same as for
the corresponding native antigens or soluble counter-
parts. A comparison was recently carried out for TB10.4
and TB10.4-Ag85B proteins [12] and, interestingly, re-
solubilized TB10.4-Ag85B purified from IBs did not
recover the conformation adopted by its counterpart
purified from the soluble fraction, but it seemed to adopt
an intermediate conformation. In order to preserve native
conformation, we produced the three antigens as soluble
proteins. The overall yields hereby achieved favourably
compare with the values reported in literature: 5 and 1 mg
of mature Ag85B and TB10.4-Ag85B per liter of cul-
tivation broth were previously produced in soluble form
[12] vs. 16 and 2.5 mg/L obtained in our conditions (see
Table 2); to our knowledge, literature data concerning
the production of mature TB10.4 as soluble protein
(vs. 25 mg/L with our procedure) were not reported.
Circular dichroism spectroscopy was used to study
secondary and tertiary protein structure. Soluble Ag85B
and His-full2 proteins have similar CD spectra. They
closely resemble those obtained previously for soluble
antigens and distinguished from TB10.4-Ag85B purified
from IBs [12]. Our procedure based on the isolation of
the proteins from the soluble fraction avoided the fol-
ding drawbacks encountered when the TB10.4-Ag85B
chimeric protein was re-solubilized from IBs [12].
The produced recombinant proteins presented an
appropriate immunogenicity as for the capability to be
recognised either by antibodies and T-cells of active-TB
patients. Interestingly, when TB10.4 was fused to Ag85B,
it presented a stronger immune-reactivity respect the
sum of the single proteins (see end final point dilution
test in Additional file 3), likely due to a better accessibi-
lity of the antigen B-cell epitope recognised by the TB-
patient antibody. A similar result was reported earlier
[6] also showing that TB10.4 distinguished from ESAT-6,
which appeared to be subdominant when fused to
Ag85B. Although less apparent, a similar result was also
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together, the fusion of TB10.4 with Ag85B did not
decrease the immunogenicity of either TB10.4 or Ag85B
and has a beneficial effect on the immunogenicity of
TB10.4.Conclusions
In conclusion, the main purpose of this study to purify
large quantities of soluble antigens effective in immuno-
logical response against M. tuberculosis was reached by
the rational design of the expression constructs and the
optimization of fermentation conditions for E. coli re-
combinant strains. The set up of a controlled, scalable,
robust and economically feasible production process
(current cost of antigenic protein production at the lab
scale is 50–100 €/mg, whereas Ag85B is commercially
available at ≥ 1800 €/mg) is important for supporting
research and development of novel vaccine candidates
to prevent and/or treat tuberculosis.Methods
Design, synthesis and cloning of cDNA coding for
antigenic proteins
Synthetic cDNAs coding for TB10.4 and Ag85B anti-
genic proteins were designed in silico by back translation
of the amino acid sequences reported in the database
(TB10.4: GenBank Accession no. CAA17363.1; Ag85B:
UniProtKB/Swiss-Prot Accession no. P0C5B9.1). A third
cDNA, in which the nucleotide sequence coding for
TB10.4 is upstream to the sequence coding for Ag85B
(full cDNA) was also designed. All synthetic cDNAs were
produced by Eurofins Medigenomix GmbH (Ebersberg,
Germany), after optimization of the nucleotidic sequences
for expression in E. coli (see Additional file 2: Figure S1).
The three synthetic genes were cloned into pET32b using
BamHI and EcoRI restriction sites. By this cloning strat-
egy, the genes were fused with thioredoxin (Trx) encoding
gene and tagged by an His6-tag. Two additional constructs
of the full cDNA were also produced. To prepare His-full1
form, the full cDNA was extracted from pET32b plasmid
using KpnI and EcoRI restriction sites and cloned into
pColdI plasmid (TaKaRa Bio Inc., Otsu, Japan). For the
production of His-full2 form, site-directed mutagenesis
was carried out on the full cDNA using the QuikChange
II Site-Directed Mutagenesis Kit (Agilent Technologies,
Santa Clara, CA, USA), to insert a NdeI restriction site at
the 5′ of the full cDNA, including the triplet coding for
the initial methionine. The following mutagenesis primers
were used: 5′GCCATGAGCTCGGATCATATGAGCCA
GATCATG3′; 5′CATGATCTGGCTCATATGATCCGAG
CTCATGGC3′ (mutated bases are in italics). The pres-
ence of the desired mutation was confirmed by automated
DNA sequencing. The mutated cDNA was then clonedinto pColdI plasmid using NdeI and EcoRI restriction
sites. The gene sequences are reported in Figure 1.
Strain and growth conditions
For protein expression, all plasmids were transferred to
the E. coli hosts BL21(DE3) and BL21(DE3)pLysS. The fol-
lowing media were used: M9/glucose (6.78 g/L Na2HPO4,
3 g/L KH2PO4, 1 g/L NH4Cl, 0.5 g/L NaCl, 0.1 mM CaCl2,
2 mM MgSO4, 10 g/L glucose); Luria-Bertani (LB, 10 g/L
bacto-tryptone, 5 g/L yeast extract, 5 g/L NaCl); Terrific
Broth (TB, 12 g/L bacto-tryptone, 24 g/L yeast extract,
8 mL/L glycerol, 2.2 g/L KH2PO4, 9.4 g/L K2HPO4);
Terrific Broth/NaCl (TB, 12 g/L bacto-tryptone, 24 g/L
yeast extract, 8 mL/L glycerol, 2.2 g/L KH2PO4, 9.4 g/L
K2HPO4, 5 g/L NaCl); Super Broth (SB, 32 g/L bacto-
tryptone, 20 g/L yeast extract, 5 g/L NaCl); Super Broth/
NaCl (SB/NaCl, 32 g/L bacto-tryptone, 20 g/L yeast ex-
tract, 10 g/L NaCl) [15,20]. Starter cultures were prepared
from a single colony of E. coli carrying the recombinant
plasmid, employing the same medium used for protein ex-
pression containing ampicillin (100 μg/mL, final con-
centration) and, in the case of BL21(DE3)pLysS strain,
also chloramphenicol (34 μg/mL, final concentration).
Cultures were grown overnight under vigorous shaking at
37°C. For chaperone co-expression, BL21(DE3) E. coli
cells were co-transformed with pKJE7 (coding for AraB,
DnaK, DnaJ and GrpE) or with pG-Tf2 (coding for GroES,
GroEL and TiG) plasmids (Chaperone Plasmid Set, TaKaRa
Bio Inc., Otsu, Japan), adding chloramphenicol (30 μg/mL,
final concentration) to the growth medium. Expression of
the chaperone proteins was induced by adding 1 mg/mL
L-arabinose (for pKJE7) or with 2 ng/mL tetracyclin (for
pG-Tf2), according to the manufacturer’s instructions.
Protein production trials were carried out in 500 mL or 2 L
baffled Erlenmeyer flasks containing 80 mL or 500 mL of
each medium inoculated with the starter cultures (initial
OD600nm = 0.1). Cells were grown at 37°C with shaking
(150 rpm) until protein expression was induced by adding
IPTG: cells were then grown at 15 or 18°C until harvesting.
Collected cells were washed with STE buffer and stored
at −20°C.
3 L bioreactor cultivations
SB for E. coli BL21(DE3) cells containing the pET32b-
Trx-Ag85B plasmid, LB for those transformed with
pET32b-Trx-TB10.4 plasmid and SB/NaCl for those
transformed with pColdI-His-full2 plasmid were used as
production media in 2 L working volume P-100 Appli-
kon 3 L glass reactor (height 25 cm, diameter 13 cm)
equipped with a AD1030 Biocontroller and AD1032
motor [20,21]. Cultivations in bioreactor were conducted
in batch-mode at 37°C, 500 rpm stirring (corresponding to
1.17 m/s of tip speed) and 2 L/min aeration rate. Foam
production was controlled by the addition of Hodag
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were grown overnight in SB, LB or SB/NaCl medium and
diluted up to an initial OD600nm of 0.1. For pET32b-Trx-
Ag85B and pET32b-Trx-TB10.4 recombinant cells, after
2–4 hours of growth (corresponding to an OD600nm of 2
for the previous and of 0.8 for the latter), 0.1 mM IPTG
was added and the temperature was decreased to 18°C.
pColdI-His-full2 recombinant cells grown for 4–6 hours
(corresponding to an OD600nm of 2) were added of
0.1 mM IPTG and 25 g/L NaCl and the temperature was
decreased to 15°C. After 16 hours, cells were harvested
by centrifugation, washed with STE buffer and stored
at −20°C.
Crude extract preparation and purification of fusion
proteins
Cell paste was re-suspended in phosphate buffer saline
(PBS) (8.1 mM Na2HPO4, 1.76 mM KH2PO4, 0.137 M
NaCl, 2.68 mM KCl), pH 7.0, 1 mM phenylmethanesul-
phonylfluride (PMSF), 10 μg/mL deoxyribonuclease. Cells
were disrupted by sonication (5 cycles of 30 s each, in ice,
with 30-s interval). The insoluble fraction was removed by
centrifugation at 39000 × g for 1 hour at 4°C. The crude
extract (added of 0.9 M NaCl) was loaded on a HiTrap
Chelating column (GE Healthcare, Piscataway, NJ, USA),
pre-loaded with Ni2+ and equilibrated in PBS, 0.9 M NaCl,
pH 7.0. Elution of the fusion protein was performed
increasing the amount of PBS buffer containing 0.5 M
imidazole, pH 7.0 [22]. The pure proteins were then
equilibrated in 20 mM TrisHCl, 50 mM NaCl, pH 7.4
by size-exclusion chromatography on a PD10 desalting
column or by extensive dialysis.
Enterokinase cleavage of the fusion proteins
Enterokinases (EK, Recombinant Enterokinase, and Tag · off
High Activity Recombinant Enterokinase) and Recombi-
nant Enterokinase Capture Agarose were purchased from
Novagen. One EK unit is defined as the amount of enzyme
that cleaves 50 μg of a control protein (supplied by the
producer) in 16 hours at room temperature and in
20 mM TrisHCl, 50 mM NaCl, 2 mM CaCl2, pH 7.4.
SDS-PAGE electrophoresis and Western blot analysis
Proteins from total cell extracts or from both soluble
and insoluble cell fractions were separated by SDS-
PAGE: gels were stained for proteins with Coomassie
Blue R-250. For total cell extracts and for insoluble
fractions after cell disruption, cell pellets were directly
resuspended in an appropriate volume of Laemmli sam-
ple buffer. For Western blot analysis, upon separation by
SDS-PAGE, proteins were transferred electrophoretically
onto a nitrocellulose membrane. The fusion proteins
were detected using anti-His-tag mouse monoclonal
antibody (His-probe, Santa Cruz Biotechnology, SantaCruz, CA, USA), rabbit anti-TB10.4 polyclonal antibodies
(Antibodies-online GmbH, Aachen, Germany), or rabbit
anti-Ag85B polyclonal antibody (DIATHEVA, Fano, Italy),
in combination with the appropriate secondary antibody:
goat anti-mouse (Santa Cruz Biotechnology, Santa Cruz,
CA, USA), donkey anti-mouse and donkey anti-rabbit
(Jackson ImmunoResearch Laboratories Inc., West Grove,
PA, USA) IgG HRP-conjugated antibody. The immunore-
cognition was detected by a chemioluminescence method
(ECL Plus Western Blotting Detection System, GE Health-
care, Piscataway, NJ, USA). The amount of protein was
estimated by evaluating the intensity of the signal using
the public domain, Java-based image processing program
ImageJ (National Institutes of Health, http://rsb.info.nih.
gov/ij/). His-tagged D-amino acid oxidase [23] was used
as standard.
Spectral measurements
Extinction coefficients of native proteins were determined
using a Jasco V-560 spectrophotometer by complete de-
naturation of appropriate dilutions of protein samples in
6 M urea assuming as extinction coefficients of the fully
denatured proteins those calculated by ExPASy Bio-
informatic Resource Portal (http://www.expasy.org/) using
ProtParam tool [24].
Circular dicroism (CD) spectra were recorded on a J-
815 Jasco spectropolarimeter [24]: cell path-lenth was
1 cm for measurements above 250 nm (0.4 mg protein/
mL) and 0.1 cm for measurements in the 190–250 nm
range (0.1 mg protein/mL). Secondary structure frac-
tions were calculated from deconvolution of the CD
spectra with the program K2D2 (http://www.ogic.ca/pro-
jects/k2d2/) [25].
Temperature ramp experiments were carried out by
using the same instrumentation equipped with a software-
driven Peltier-based temperature controller (temperature
gradient: 0.5°C/min). All spectral experiments were carried
out in 20 mM MOPS, 0.4 M NaCl, pH 7.0 or in 10 mM
ammonium acetate, pH 7.0 at 15°C.
Mass spectrometry analyses
Intact MS experiments were in general carried out on a
LTQ-MS (Thermo Electron, San Jose, CA, USA) with an
ESI source. The protein samples were prepared in
10 mM ammonium bicarbonate (pH 7.4), 0.1% aceto-
nitrile/trifluroacetic acid (50/50) to a final concentration
of 0.3 mg/mL. Full scan intact MS experiments were
carried out under the following instrumental conditions:
positive ion mode, mass range 700–2000 m/z, source
voltage 4.5 kV, capillary voltage 35 V, sheat gas 15, auxiliary
gas 2, capillary temperature 220°C, tube lens voltage 140 V.
Five spectra were acquired for each data and each spectrum
was the composite of two averaged scans. Data processing
was performed using Bioworks Browser (Thermo Electron,
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Ion Source Bioinformatic Resource Portal (http://www.
ionsource.com/) using Peptide Mass Calculator tool. Iden-
tification of truncated forms of the proteins was carried
out by MS-non specific database search program Protein
Prospector v 5.10.4 (http://prospector.ucsf.edu).
The His-full2 protein was dissolved in acetonitrile and
analyzed using a MALDI-TOF/TOF Ultraflex III spec-
trometer (Bruker Daltonics, Bremen, Germany) in linear
positive mode. A solution of sinapinic acid (SA) 20 mg/mL
solved in a 70/30 acetonitrile/trifluoroacetic acid (TFA)
0.1% solution, was used as matrix. The spectra were acqui-
red in a mass range of 6000–52000 m/z and processed
using Flex Analysis software 3.0 (Bruker Daltonics).
Immunological studies: study population
The study population included 19 subjects. Twelve pa-
tients with newly diagnosed, untreated active pulmonary
TB and 7 healthy individuals without any history of TB
exposure (hereafter indicated as TB unexposed controls).
Study subjects were recruited at the Department of
Infectious Diseases of the Fondazione IRCCS-Policlinico
San Matteo of Pavia (Italy), after informed consent. In
all cases, the diagnosis of active TB was confirmed by M.
tuberculosis culture isolation.
Peripheral venous blood was obtained for serum samples
from all the participants to the study to perform ELISA
assay. Additionally, peripheral blood was collected into
tubes containing heparin for ELISPOT assay. Peripheral
blood mononuclear cells (PBMC) were isolated by stan-
dard density gradient centrifugation using Lymphoprep
(Axis-Shield, Oslo, Norway). Isolated PBMC were cryo-
preserved in freezing medium: 10% v/v DMSO (Sigma-
Aldrich, St. Louis, MO, USA), 25% v/v human albumin
(Grifolds Biologicals, Los Angeles, CA, USA) and 65% v/v
RPMI 1640 supplemented with 2 mM L-glutamine,
100 U/mL penicillin and 100 μg/mL streptomycin (all
from Euroclone, Milan, Italy) and kept in liquid nitrogen
until ELISPOTanalyses.
ELISA assay
ELISA assay was performed with the method of [26]
with minor modifications. Microplates 96-wells high-
binding capacity flat-bottom (Greiner-bio-one GmbH,
Frickenhausen Germany) were coated with different con-
centrations (400, 200, 100 ng/well) of Ag85B, TB10.4, His-
full2 in 50 mM bicarbonate buffer (pH 9.6) and incubated
at room temperature overnight. Plates were washed three
times with 0.05% (v/v) Tween-20 in phosphate buffered
saline (PBS-T, Sigma-Aldrich, St. Louis, MO, USA) and
incubated with 200 μL/well of blocking buffer (PBS with
1% BSA) at room temperature for at least 1 hour and then
washed three times with PBS-T. Serum samples were di-
luted with dilution buffer (PBS-T with 1% BSA) at scalardilution of 1:50 to 1:800. One-hundred microliter of the
diluted sera was added to each well and incubated for
1 hour at 37°C. Plates were then washed four times with
PBS-T. Anti-human specific IgG antibody labeled with
horseradish peroxidase (MP Biomedicals, LLC Santa Ana,
CA, USA) was added to each well and incubated at 37°C
for 1 hour. Plates were again washed four times with
PBS-T and 100 μL of o-phenyl-diamine/H2O2 substrate
(Sigma-Aldrich, St. Louis, MO, USA) was added for 30 mi-
nutes. The reaction was stopped by adding 50 μL of 0.5 M
H2SO4. The absorbance at 492 nm was measured with an
ELISA plate spectrophotometer (Titertek Plus MS212
ICN, Eschwege, Germany).
Evaluation of peptide specific single T-cell IFN-γ release
The enumeration of peptide specific T-cell producing
IFN-γ was performed at the single cell level by using
ELISPOT assay, as previously described, with minor
modifications [27].
In detail, PBMC were thawed, washed and re-suspended
in the culture medium: RPMI 1640 medium supple-
mented with 2 mM L-glutamine, 100 U/mL penicillin,
100 μg/mL streptomycin and 10% heat-inactivated fetal
calf serum (Euroclone, Milan, Italy). Cells were kept
overnight at 37°C in a humidified 5% CO2 atmosphere.
Cells were then transferred to a 24-well flat-bottom plate
(5 × 105 cells/mL per well), stimulated with 1 μg/mL of
each protein (one protein per well) or culture medium
only or phytohemagglutinin (PHA) (5 μg/mL; Sigma-
Aldrich, St. Louis, MO, USA), and cultured at 37°C in a
humidified 5% CO2 atmosphere for 10 days. On days 3
and 7, half of the supernatant from each well was removed
and replaced with wet culture medium supplemented with
20 IU/mL recombinant human IL-2 (Peprotech, London,
UK). After 10 days, cells from each well were harvested,
washed three times with culture medium and re-
suspended at a concentration of 4 × 105 cells/mL before
their use in ELISPOT assay. Un-stimulated PBMC were
included as negative controls.
In ELISPOT assay, multiScreen-IP 96-well plates
(Merck Millipore, Darmstadt, Germany) were coated
with IFN-γ capture antibody and incubated overnight at
4°C. Plates were then washed 5 times with PBS and
blocked with culture medium for 2 hours at room
temperature. Antigen-stimulated cells for 10 days were
added in duplicate (4 × 104 cells/well) and re-stimulated
with each protein used for stimulation during the 10-day
period. Cells stimulated with PHA during the 10-day
period were re-stimulated with Staphylococcus aureus
Enterotoxin B (SEB) superantigen (2 μg/mL; Sigma-
Aldrich, St. Louis, MO, USA). After incubation at 37°C in
a humidified 5% CO2 atmosphere for 24 hours, plates
were washed five times with PBS-T (Sigma-Aldrich, St.
Louis, MO, USA). Biotinylated detection antibody for
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five washes with PBS-T, streptavidin-alkaline phosphatase
conjugate was added and plates were incubated at 37°C,
5% CO2 atmosphere for 1 hour. Plates were then washed,
5-bromo-4-chloro-3-indolyl-phosphate/nitro blue tetrazo-
lium (BCIP/NBT) was added and incubated at room
temperature for 20 minutes. Wells were then washed
several times under running water and air-dried. Spot-
forming cells (SFCs) were counted in duplicate wells using
an automated ELISPOT reader system (Autoimmun Diag-
nostika GmbH, Strassberg, Germany). The mean value of
the SFCs was calculated, and the value of the control
subtracted to the SFCs of the stimuli: values were referred
to million PBMC.Statistical analysis
Data are expressed using mean and standard deviation
of the mean or median and percentiles as appropriate.
Comparison between groups have been made using
Mann–Whitney and χ2 tests. A p value below 0.05 was
considered significant. All tests were performed using
the GraphPad Prism 4.0 (Graphpad software, San Diego,
CA, USA) software package.Additional files
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